Order For Withdrawal Of Mifepristone Would Be ‘Unprecedented,’ Seismic Event; Wyden Says FDA Must Ignore It
Executive Summary
Senator Wyden says the case has been "a rigged game all along" as state attorneys general and medical groups file briefs in the suit against the FDA.
You may also be interested in...
Can Courts And States Override FDA’s Drug Regulatory Authority?
Dueling suits seek to force US FDA to withdraw approval of mifepristone or prevent it from doing so while legislation introduced in Idaho would outlaw the use of mRNA technology. Lawyers say these are worrisome challenges to the agency's scientific judgement.
Mifepristone REMS For Pharmacies Contains Some Unusual Provisions, Continues Debate Over Access
After FDA clears modified REMS, certified retail pharmacists are permitted to dispense the abortion medication. Some advocates argue program is unnecessary, while others want a broader federal effort to expand access. Walgreens intends to become a certified pharmacy.
What Will FDA Do In Battle Over Medication Abortion Access?
Attorneys discuss host of questions the agency faces in the wake of the Dobbs decision, including whether to take enforcement action against mifepristone REMS violations, whether to change restrictions on its use, and how to deal with challenges to its drug approval authority.